RxDoctor Payments Data

Robert Richardson, MD

Neurology · Bedford, OHNPI 1285671578

Payments from drug & device makers

$199in general payments, 2019–2025

Across 12 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$80
  • Impel Pharmaceuticals Inc.$34
  • Genentech USA, Inc.$23
  • Pfizer$20
  • Novartis$16
  • Biohaven Pharmaceutical Holding Company Ltd.$15
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$199100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$199 in reported general payments places this provider in the 25th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$67,128
Medicare patients
301
Services billed
1,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MayzentSiponimod12$128,181
GlatopaGlatiramer Acetate35$96,757
CopaxoneGlatiramer Acetate12$70,544
AmpyraDalfampridine12$44,340
Aimovig AutoinjectorErenumab-Aooe40$41,476
Dimethyl Fumarate42$37,410
QuliptaAtogepant31$33,439
Glatiramer Acetate21$32,110
Rufinamide11$29,798
Nurtec OdtRimegepant Sulfate14$24,774
Emgality PenGalcanezumab-Gnlm29$22,268
FingolimodFingolimod Hcl13$21,621
Ajovy AutoinjectorFremanezumab-Vfrm19$12,751
Levetiracetam254$10,366
TegretolCarbamazepine18$10,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent$16$128,18112 claims
AbbVieQulipta$80$33,43931 claims
PfizerNurtec Odt$20$24,77414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 702 neurology providers in Ohio.

Other neurology in Bedford

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →